Cardinal Health Inc Q3 Income Falls

Cardinal Health reported Q3 GAAP earnings of $399 million, or $1.69 per share, down from $506 million, or $2.10 per share, a year ago, while revenue rose 11.0% to $60.94 billion from $54.88 billion. Adjusted EPS was $3.17 on $750 million of adjusted earnings. The company also guided full-year EPS to $10.70-$10.80.

Analysis

The key read-through is not the headline EPS decline but the durability of volume and pricing in a low-margin distribution model. An 11% top-line increase on this base implies Cardinal is still gaining from scale, and that matters more than quarter-to-quarter GAAP noise because incremental spread capture in pharma distribution tends to show up slowly but compounds through working capital efficiency and mix. The market should focus on whether this is evidence of continued share stability versus peers; if so, the real winner is Cardinal’s negotiating leverage with manufacturers and specialty-channel partners, not the reported earnings line.

Guidance is the bigger signal: management is still comfortable anchoring the year around a tighter EPS band despite the year-over-year profit compression, which suggests there is some cushion from operating leverage or capital allocation rather than a one-off demand spike. The second-order effect is on competitors with less scale or weaker purchasing power, who may be forced to defend share with lower margins if Cardinal keeps using its balance sheet to fund inventory and service levels. That dynamic is especially relevant in healthcare distribution, where small changes in fill rates or contract retention can cascade into multi-quarter share shifts.

The main risk is that this is a volume story masking margin fragility: if reimbursement pressure, mix degradation, or inventory normalization hits over the next 1-2 quarters, the market could quickly re-rate the name back to a lower multiple. The contrarian view is that consensus may be overemphasizing the GAAP decline; in this business, cash conversion and contract stability often matter more than reported EPS, so the setup favors buying weakness if guidance confidence holds into the next print.

Key Decisions for Investors

• Long CAH on any post-earnings pullback of 3-5%: treat as a defensive compounder with low downside if guidance holds; target a 2-3 month mean reversion into the high-single-digit forward multiple.
• Pair trade: long CAH / short a weaker healthcare distributor or pharmacy-services proxy over the next 1-3 months to isolate scale and pricing power; this is attractive if the market starts rewarding stable guidance over headline margin noise.
• Sell out-of-the-money puts in CAH for the next 30-45 days if implied vol stays elevated; the skew looks richer than the fundamental surprise, and downside should be cushioned by the guided EPS floor.
• Watch for a second-quarter read-through on gross margin and inventory days; if working capital starts to stretch, reduce exposure quickly because the thesis breaks if growth is being funded by balance-sheet intensity rather than real operating leverage.